Genomic Test Helps Guide Precision Medicine to Estimate Risk of Prostate Cancer Metastasis, Death
February 11, 2021
San Francisco, CA (UroToday.com) A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers.
Researchers studied prostate cancer samples from 352 participants in the NRG/RTOG 9601 clinical trial, which compared radiation therapy alone with radiation therapy combined with hormone therapy. The investigators found that the Decipher test, which measures the activity of 22 genes among seven known cancer pathways, independently estimated the participants’ risk of metastasis, death from prostate cancer, and overall survival. Researchers say it also guided treatment recommendations for recurrence of prostate cancer after surgery, helping identify patients most likely to bene